Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Stopped early · Phase 2
Conditions studied: Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
In brief
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying the side effects and how well low-dose decitabine works in treating patients with symptomatic myelofibrosis.
Key facts
- Study ID
- NCT00630994
- Run by
- Mayo Clinic
- People needed
- 4
- Starts
- 2008-03-01
- Expected to finish
- 2012-04-01
- Last updated by the study team
- 2015-12-30
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.